Free tool
Drug Trial Radar: Neurology
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
845
Completed, industry sponsors, Neurology, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
- Recruiting120
- Completed845
845 trials
Showing 1 to 25, recently updated first.
Mapi Pharma Ltd.Industry
NCT02212886 · 25 participants · Start Oct 2014 · Primary completion May 2017
Drug: GA Depot 80 mg; GA Depot 40 mg · For: Multiple Sclerosis
Sites: Ashkelon, Israel; Haifa, Israel; Tel Aviv, Israel
- Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's DiseaseCompleted
Vertero TherapeuticsIndustry
NCT07310264 · 80 participants · Start Oct 30, 2025 · Primary completion Nov 10, 2026
Drug: VT-5006; Placebo · For: Healthy Volunteers (HV); Parkinson's Disease (PD)
Sites: Leiden, Netherlands
Neumora Therapeutics, Inc.Industry
NCT06546995 · 87 participants · Start Jul 9, 2024 · Primary completion Nov 19, 2025
Drug: NMRA-323511; Placebo · For: Alzheimer's Disease; Healthy Elderly
Sites: Chandler, Arizona; Tempe, Arizona; Costa Mesa, California · 26 sites in all
Axxium Life, Inc.Industry
NCT05477095 · 40 participants · Start Jul 6, 2022 · Primary completion Oct 6, 2023
Drug: UB-313; Placebo · For: Migraine
Sites: Leuven, Belgium
AnHorn Medicines Co. Ltd.Industry
NCT07697560 · 32 participants · Start Jun 10, 2026 · Primary completion Sep 25, 2026
Drug: AH-008 for Injection, 150 mg; AH-008 for Injection, Placebo · For: Chemotherapy-induced Peripheral Neuropathy (CIPN)
Sites: Salt Lake City, Utah
Life Molecular Imaging GmbHIndustry
NCT04715750 · 10 participants · Start Nov 12, 2020 · Primary completion Oct 26, 2022
Drug: [18F]-PI2620 · For: Alzheimer Disease; Progressive Supranuclear Palsy
Sites: Leipzig, Germany
Lantheus Germany GmbHIndustry
NCT06790394 · 15 participants · Start Oct 21, 2025 · Primary completion Oct 7, 2026
Drug: Florbetaben F18 · For: Cardiac Amyloidosis
Sites: London, United Kingdom · 2 sites in all
Neurelis, Inc.Industry
NCT05076838 · 36 participants · Start Nov 8, 2021 · Primary completion Mar 11, 2025
Drug: Diazepam Nasal Spray [Valtoco] · For: Epilepsy
Sites: Gulf Breeze, Florida; Miami, Florida; Orlando, Florida · 13 sites in all
AstraZenecaAstraZeneca (AZN)
NCT03423628 · 159 participants · Start Apr 2, 2018 · Primary completion Aug 31, 2026
Drug: AZD1390; AZD1390 and 1 more · For: Recurrent Glioblastoma Multiforme; Primary Glioblastoma Multiforme; Brain Neoplasms, Malignant and 1 more
Sites: Boston, Massachusetts; New York, New York; Pittsburgh, Pennsylvania · 11 sites in all
- Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04626479 · 393 participants · Start Dec 16, 2020 · Primary completion Aug 10, 2026
Drug: Pembrolizumab; Favezelimab/Pembrolizumab and 4 more · For: Carcinoma, Renal Cell
Sites: San Francisco, California; New Haven, Connecticut; Chicago, Illinois · 55 sites in all
- Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04626518 · 263 participants · Start Dec 17, 2020 · Primary completion Jul 23, 2026
Drug: Pembrolizumab; MK-4830 and 4 more · For: Carcinoma, Renal Cell
Sites: San Francisco, California; New Haven, Connecticut; Chicago, Illinois · 51 sites in all
Regeneration Biomedical, Inc.Industry
NCT05667649 · 7 participants · Start Aug 14, 2023 · Primary completion Jun 25, 2026
Drug: RB-ADSC · For: Alzheimer Disease
Sites: Newport Beach, California
Nuravax, Inc.Industry
NCT06831812 · 16 participants · Start Jun 12, 2024 · Primary completion Dec 1, 2025
Drug: AV-1959R (Abeta vaccine) · For: Alzheimer Disease; Alzheimer Disease (AD); Alzheimers Disease Prevention
Sites: Adelaide, Australia
TakedaTakeda (TAK)
NCT02497235 · 11 participants · Start Jul 2015 · Primary completion Dec 2015
Drug: TAK-935; [18F]MNI-792 (tracer) · For: Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents
Sites: New Haven, Connecticut
TakedaTakeda (TAK)
NCT02539134 · 40 participants · Start Sep 2015 · Primary completion Apr 2016
Drug: TAK-935; Placebo · For: Epilepsy
Sites: Austin, Texas
EMD Serono Research & Development Institute, Inc.Industry
NCT05882734 · 61 participants · Start Sep 13, 2023 · Primary completion Jul 15, 2026
Drug: M1774; Cemiplimab · For: Non-Small Cell Lung Cancer
Sites: Santa Monica, California; Pittsburgh, Pennsylvania; Knoxville, Tennessee · 54 sites in all
TakedaTakeda (TAK)
NCT03166215 · 18 participants · Start Aug 17, 2017 · Primary completion Sep 19, 2018
Drug: TAK-935; Placebo · For: Developmental and/or Epileptic Encephalopathies
Sites: Phoenix, Arizona; Port Charlotte, Florida; Tampa, Florida · 11 sites in all
Kura Oncology, Inc.Industry
NCT04997902 · 45 participants · Start Dec 7, 2021 · Primary completion Aug 29, 2025
Drug: Tipifarnib; Alpelisib · For: HNSCC
Sites: Duarte, California; Orlando, Florida; Baltimore, Maryland · 11 sites in all
PfizerPfizer (PFE)
NCT07594769 · 36 participants · Start May 11, 2026 · Primary completion Sep 1, 2026
Drug: ODT2 Test formulation; ODT Reference formulation · For: Migraine
Sites: Brussels, Belgium
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT05466422 · 34 participants · Start Sep 20, 2022 · Primary completion Jul 3, 2025
Drug: MK-2214; Placebo · For: Alzheimer Disease
Sites: Glendale, California; Los Alamitos, California; Orange, California · 12 sites in all
- Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04305041 · 100 participants · Start Jun 26, 2020 · Primary completion Aug 25, 2025
Drug: Pembrolizumab; Quavonlimab and 3 more · For: Melanoma
Sites: Los Angeles, California; Santa Monica, California; Aurora, Colorado · 36 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06460961 · 40 participants · Start Jul 14, 2024 · Primary completion Jul 29, 2026
Drug: MK-6837; Pembrolizumab and 1 more · For: Neoplasm Metastasis
Sites: Morristown, New Jersey; Portland, Oregon; San Antonio, Texas · 7 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT04303169 · 146 participants · Start Jun 26, 2020 · Primary completion Sep 24, 2025
Drug: Pembrolizumab; Vibostolimab and 4 more · For: Melanoma
Sites: Los Angeles, California; Santa Monica, California; Aurora, Colorado · 29 sites in all
Shanghai WD Pharmaceutical Co., Ltd.Industry
NCT05128175 · 15 participants · Start Oct 29, 2021 · Primary completion Dec 9, 2021
Drug: WD-1603 Carbidopa-Levodopa Extended-Release Tablets · For: Parkinson Disease
Sites: Ahmedabad, India
Shenzhen Protgen Co., Ltd.Industry
NCT06489015 · 30 participants · Start Aug 27, 2024 · Primary completion Apr 14, 2026
Drug: Recombinant Human Serum Albumin · For: Alzheimer's Disease (AD)
Sites: Luoyang, China; Zhengzhou, China; Wuhan, China · 5 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.